PTC Therapeutics said on Monday that it would receive a net price of $35,000 annually per patient for Emflaza, the muscular dystrophy drug it acquired from Marathon Pharmaceuticals last month.
from WSJ.com: US Business http://ift.tt/2qSODN4
via IFTTT
No comments:
Post a Comment